This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Biopure (BPURD) rose 19.5% after it said the U.S. Naval Medical Research Center has applied to the FDA for approval to conduct a two-stage clinical trial of the company's oxygen therapeutic Hemopure drug for the out of hospital treatment of trauma patients, where blood is not available for transfusion.

If the trial is approved, the phase II and III of the study will assess the safety and efficacy of Hemopure compared with standard treatment of hemorrhagic shock (acute blood loss). Patients would be randomized to receive either Hemopure or standard therapy of the injury and during transport to the hospital. The company said the trial would require an exception from informed consent and would include a community consultation and disclosure program, as defined in federal regulations. To date, Congress has appropriated $18.5 million to the military to develop Hemopure for potential military and civilian use. Biopure Corporation develops and manufacturers intravenously administered pharmaceuticals, called oxygen therapeutics. The stock finished up 26 cents to $1.59.

Other health stocks on the move were Merck (MRK), up 16 cents to $31.55; Pfizer (PFE), up 21cents to $27.89; Elan (ELN), down 35 cents to $6.78; Biogen, down 22 cents to $34.79; and Johnson & Johnson (JNJ), down a penny to $66.47.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ELN $0.00 0.00%
BIIB $301.66 -0.84%
GE $24.54 -0.12%
MSON $11.05 1.50%
AAPL $110.51 -1.60%

Markets

Chart of I:DJI
DOW 16,374.76 +23.38 0.14%
S&P 500 1,951.13 +2.27 0.12%
NASDAQ 4,733.4970 -16.4820 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs